UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease

World journal of gastroenterology : WJG, 2024-07, Vol.30 (28), p.3428-3446

2024

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice

World journal of gastroenterology : WJG, 2022-05, Vol.28 (17), p.1814-1829

2022

Volltextzugriff (PDF)

Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer

Oncotarget, 2016-03, Vol.7 (13), p.15577-15599

2016

Volltextzugriff (PDF)

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes

Diabetes, obesity & metabolism, 2012-11, Vol.14 (11), p.973-982

Wilding, J. P. H.

2012

Volltextzugriff (PDF)

Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

Oncotarget, 2017-07, Vol.8 (28), p.46273-46285

2017

Volltextzugriff (PDF)

PPARα agonist relieves spinal cord injury in rats by activating Nrf2/HO-1 via the Raf-1/MEK/ERK pathway

Aging (Albany, NY.), 2021-11, Vol.13 (22), p.24640-24654

2021

Volltextzugriff (PDF)

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

Diabetes, obesity & metabolism, 2020-01, Vol.22 (1), p.30-38

2020

Volltextzugriff (PDF)

Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013)

Oncotarget, 2017-03, Vol.8 (10), p.16912-16924

2017

Volltextzugriff (PDF)

Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice

Diabetes, obesity & metabolism, 2018-07, Vol.20 (7), p.1688-1701

2018

Volltextzugriff (PDF)

Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro

International journal of clinical and experimental pathology, 2015-01, Vol.8 (10), p.12216-12224

2015

Volltextzugriff (PDF)

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial

Diabetes, obesity & metabolism, 2016-07, Vol.18 (7), p.711-715

2016

Volltextzugriff (PDF)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

Medical science monitor, 2016-03, Vol.22, p.743-751

2016

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor α,a potential therapeutic target for alcoholic liver disease

World journal of gastroenterology : WJG, 2014-07, Vol.20 (25), p.8055-8060

2014

Volltextzugriff (PDF)

Astragalus root induces ovarian β‑oxidation and suppresses estrogen‑dependent uterine proliferation

Molecular medicine reports, 2018-12, Vol.18 (6), p.5198-5206

2018

Volltextzugriff (PDF)

Metabolism of methiocarb and carbaryl by rat and human livers and plasma, and effect on their PXR, CAR and PPARα activities

The Journal of Toxicological Sciences, 2016/10/01, Vol.41(5), pp.677-691

2016

Volltextzugriff (PDF)

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat

Diabetes, obesity & metabolism, 2013-02, Vol.15 (2), p.164-174

2013

Volltextzugriff (PDF)

Biochanin A ameliorates the cytokine secretion profile of lipopolysaccharide-stimulated macrophages by a PPARγ-dependent pathway

Molecular medicine reports, 2012-01, Vol.5 (1), p.217-222

2012

Volltextzugriff (PDF)

Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-α/δ activation and increased mitochondrial fatty acid oxidation

Diabetes, obesity & metabolism, 2009-04, Vol.11 (4), p.304-314

2009

Volltextzugriff (PDF)

Detection of non-genotoxic hepatocarcinogens and prediction of their mechanism of action in rats using gene marker sets

The Journal of Toxicological Sciences, 2016/04/01, Vol.41(2), pp.281-292

2016

Volltextzugriff (PDF)

Targeting Apoptosis in the Heart of Streptozotocin-Induced Diabetic Rats

Journal of cardiovascular pharmacology and therapeutics, 2010-06, Vol.15 (2), p.175-181

2010

Volltextzugriff (PDF)

Fibrate Therapy: An Update

Cardiology in review, 2008-05, Vol.16 (3), p.129-141

2008

Volltextzugriff (PDF)

Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice

Diabetes, obesity & metabolism, 2010-03, Vol.12 (3), p.234-245

2010

Volltextzugriff (PDF)

Transcriptome analyses demonstrate that Peroxisome Proliferator-Activated Receptor α (PPARα) activity of an ultraviolet absorber, 2-(2’-hydroxy-3’,5’-di-tert-butylphenyl)benzotriazole, as possible mechanism of their toxicity and the gender differences

The Journal of Toxicological Sciences, 2016/10/01, Vol.41(5), pp.693-700

2016

Volltextzugriff (PDF)

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (4), p.209-216

2010

Volltextzugriff (PDF)

Activation of PPAR γ and α by Punicic Acid Ameliorates Glucose Tolerance and Suppresses Obesity-Related Inflammation

Journal of the American College of Nutrition, 2009-04, Vol.28 (2), p.184-195

2009

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(62)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Ppar Alpha - Agonists
(81)
Humans
(64)
Animals
(60)
Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Ppar Gamma - Agonists
(40)
Male
(27)
Ppar Alpha - Metabolism
(26)
Rats
(19)
Diabetes Mellitus, Type 2 - Drug Therapy
(15)
Mice
(15)
Fenofibrate - Pharmacology
(14)
Female
(12)
Hypoglycemic Agents - Therapeutic Use
(12)
Insulin Resistance
(12)
Liver - Metabolism
(12)
Hypoglycemic Agents - Pharmacology
(11)
Thiazolidinediones - Pharmacology
(11)
Disease Models, Animal
(10)
Peroxisome Proliferator-Activated Receptors
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease

Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice

Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes

Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

PPARα agonist relieves spinal cord injury in rats by activating Nrf2/HO-1 via the Raf-1/MEK/ERK pathway

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013)

Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice

Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

Peroxisome proliferator-activated receptor α,a potential therapeutic target for alcoholic liver disease

Astragalus root induces ovarian β‑oxidation and suppresses estrogen‑dependent uterine proliferation

Metabolism of methiocarb and carbaryl by rat and human livers and plasma, and effect on their PXR, CAR and PPARα activities

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat

Biochanin A ameliorates the cytokine secretion profile of lipopolysaccharide-stimulated macrophages by a PPARγ-dependent pathway

Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-α/δ activation and increased mitochondrial fatty acid oxidation

Detection of non-genotoxic hepatocarcinogens and prediction of their mechanism of action in rats using gene marker sets

Targeting Apoptosis in the Heart of Streptozotocin-Induced Diabetic Rats

Fibrate Therapy: An Update

Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice

Transcriptome analyses demonstrate that Peroxisome Proliferator-Activated Receptor α (PPARα) activity of an ultraviolet absorber, 2-(2’-hydroxy-3’,5’-di-tert-butylphenyl)benzotriazole, as possible mechanism of their toxicity and the gender differences

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus

Activation of PPAR γ and α by Punicic Acid Ameliorates Glucose Tolerance and Suppresses Obesity-Related Inflammation

Aktive Filter

Suchergebnisse filtern